Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part I - Barriers and determining factors in ocular delivery

被引:108
作者
Sanchez-Lopez, E. [1 ,2 ]
Espina, M. [1 ,2 ]
Doktorovova, S. [3 ]
Souto, E. B. [3 ,4 ]
Garcia, M. L. [1 ,2 ]
机构
[1] Univ Barcelona, Dept Pharm Pharmaceut Technol & Phys Chem, Fac Pharm, Av Joan 23 S-N, E-08028 Barcelona, Spain
[2] Univ Barcelona, Inst Nanosci & Nanotechnol, Av Joan 23 S-N, E-08028 Barcelona, Spain
[3] Univ Coimbra FFUC, Dept Pharmaceut Technol, Fac Pharm, Polo Ciencias Saude, Azinhaga Santa Comba, P-3000548 Coimbra, Portugal
[4] Univ Coimbra, Grp Pharmaceut Technol, Fac Pharm, REQUIMTE LAQV, Coimbra, Portugal
关键词
Ocular drug delivery; Ocular barriers; Drug transport; Eye physiology; Lipid nanoparticles; SYSTEMIC DRUG-DELIVERY; PLGA NANOSPHERES; EX-VIVO; STRATEGIES; TRANSPORT; FLURBIPROFEN; METABOLISM; DISEASES; RELEASE; SEGMENT;
D O I
10.1016/j.ejpb.2016.10.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ocular drug delivery is still a challenge for researchers in the field of pharmaceutical technology due to anatomical and physiological eye characteristics. The tissue barriers (such as cornea, conjunctiva, blood aqueous barrier, and blood-retinal barrier) limit the access of drugs to their targets. Taking into account the short retention time in the precorneal area of classical ocular dosage forms (e.g. solutions, suspensions or ointments) which are rapidly eliminated by tears and eyelid movement, only less than five percent of the administered drug attains intraocular structures. With the aim to overcome ocular barriers, drug delivery systems, able to increase ocular bioavailability reducing side effects, are recognized as promising alternative. In this review, the main barriers and strategies to increase drug transport in ocular delivery are comprehensively discussed, highlighting the factors involved in ocular transport of SLN and NLC. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:70 / 75
页数:6
相关论文
共 50 条
[1]   Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration [J].
Abrego, Guadalupe ;
Alvarado, Helen ;
Souto, Eliana B. ;
Guevara, Bessy ;
Halbaut Bellowa, Lyda ;
Parra, Alexander ;
Calpena, Ana ;
Luisa Garcia, Maria .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2015, 95 :261-270
[2]   Colloidal drug delivery system: amplify the ocular delivery [J].
Ameeduzzafar ;
Ali, Javed ;
Fazil, Mohd ;
Qumbar, Mohd ;
Khan, Nazia ;
Ali, Asgar .
DRUG DELIVERY, 2016, 23 (03) :710-726
[3]  
Barar J, 2008, EXPERT OPIN DRUG DEL, V5, P567, DOI [10.1517/17425247.5.5.567, 10.1517/17425247.5.5.567 ]
[4]   Drug metabolism and pharmacokinetics [J].
Benedetti, Margherita Strolin ;
Whomsley, Rhys ;
Poggesi, Italo ;
Cawello, Willi ;
Mathy, Francois-Xavier ;
Delporte, Marie-Laure ;
Papeleu, Peggy ;
Watelet, Jean-Baptiste .
DRUG METABOLISM REVIEWS, 2009, 41 (03) :344-390
[5]   Ocular drug delivery: a clue from nanotechnology [J].
Bucolo, Claudio ;
Drago, Filippo ;
Salomone, Salvatore .
FRONTIERS IN PHARMACOLOGY, 2012, 3
[6]   Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin [J].
Cavalli, R ;
Gasco, MR ;
Chetoni, P ;
Burgalassi, S ;
Saettone, MF .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 238 (1-2) :241-245
[7]  
Cholkar K, 2012, WOODH PUB SER BIOMED, P1, DOI 10.1533/9781908818317.1
[8]  
Cholkar Kishore, 2012, Recent Pat Nanomed, V2, P82
[9]   Novel Strategies for Anterior Segment Ocular Drug Delivery [J].
Cholkar, Kishore ;
Patel, Sulabh P. ;
Vadlapudi, Aswani Dutt ;
Mitra, Ashim K. .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 29 (02) :106-123
[10]   Delivery strategies for treatment of age-related ocular diseases: From a biological understanding to biomaterial solutions [J].
Delplace, Vianney ;
Payne, Samantha ;
Shoichet, Molly .
JOURNAL OF CONTROLLED RELEASE, 2015, 219 :652-668